Chronic Spontaneous Urticaria Market: Rapid Increment Driven by Innovation by 2034 - DelveInsight

DelveInsight's report, "Chronic Spontaneous Urticaria Market Insights, Epidemiology, and Market Forecast-2034" provides a comprehensive analysis of the Chronic Spontaneous Urticaria landscape. The report delivers detailed insights into the disease, including historical and projected epidemiology, helping stakeholders understand the prevalence, incidence, and patient demographics across key regions.

Additionally, it examines Chronic Spontaneous Urticaria market dynamics, offering a thorough assessment of current and emerging market trends, treatment patterns, and therapeutic developments. The analysis spans major markets, including the United States, EU4 (Germany, Spain, Italy, France, and the United Kingdom), and Japan, equipping decision-makers with actionable intelligence for strategic planning, investment, and research initiatives.

To Know in detail about the Chronic Spontaneous Urticaria market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Chronic Spontaneous Urticaria Market Forecast
https://www.delveinsight.com/sample-request/chronic-spontaneous-urticaria-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Some of the key facts of the Chronic Spontaneous Urticaria Market Report:
• The Chronic Spontaneous Urticaria market size across the 7MM was valued at approximately USD 2,000 million in 2025 and is projected to grow at a CAGR of 15.9%, reaching around USD 7,555 million by 2034 across key markets, including the US, EU4, the UK, and Japan.
• In September 2025, Novartis announced that Rhapsido® (remibrutinib) has been approved by the U.S. Food and Drug Administration (FDA) as an oral therapy for adults with chronic spontaneous urticaria (CSU) who continue to experience symptoms despite treatment with H1 antihistamines. The medication is taken twice daily in pill form and eliminates the need for injections or routine lab monitoring. It is the first FDA-approved Bruton's tyrosine kinase inhibitor (BTKi) for CSU, working by targeting BTK to reduce the release of histamine and other proinflammatory mediators, thereby offering a novel treatment approach.
• In April 2025, Sanofi and Regeneron's Dupixent (dupilumab) has received approval from the U.S. Food and Drug Administration (FDA) for the treatment of chronic spontaneous urticaria (CSU).
• In 2024, the US Chronic Spontaneous Urticaria market was valued at around USD 1 billion and is expected to grow at a CAGR of 14% over the forecast period, supported by rising disease awareness and the introduction of emerging therapies.
• In 2024, the combined Chronic Spontaneous Urticaria market in the EU4 and the UK was estimated at approximately USD 620 million, accounting for nearly 30% of total 7MM market revenues.
• Within the EU4 and the UK, Germany represented the largest Chronic Spontaneous Urticaria market at approximately USD 165 million in 2024, whereas Spain recorded the smallest market, at around USD 80 million.
• In 2024, biologics led the Chronic Spontaneous Urticaria treatment landscape across the 7MM, accounting for the largest market share with revenues of roughly USD 1 billion. Prescription antihistamines followed with about USD 490 million in revenue, while immunosuppressive agents generated approximately USD 215 million, underscoring the strong shift toward targeted biologic therapies observed in Chronic Spontaneous Urticaria clinical trials.
• In 2024, Japan's Chronic Spontaneous Urticaria market was valued at nearly USD 335 million and is expected to evolve by 2034.
• LOU064 (remibrutinib) is expected to surpass USD 1.5 billion in sales across the 7MM by 2034, underscoring its significant commercial promise as a leading emerging therapy in the Chronic Spontaneous Urticaria market.
• As per DelveInsight's estimates, around 4.5 million diagnosed prevalent cases of chronic urticaria were recorded across the 7MM in 2024, and this figure is expected to rise by 2034.
• Within the 7MM, the United States represented nearly 19% of all diagnosed prevalent chronic urticaria cases, with approximately 885,000 patients in 2024, and this figure is expected to evolve over the forecast period (2025-2034). In the same year, the EU4 and the UK together accounted for about 39% of cases, while Japan contributed roughly 42% of the total.
• According to DelveInsight's estimates, type-specific diagnosed prevalent cases of chronic urticaria in the 7MM in 2024 included approximately 3.2 million cases of Chronic Spontaneous Urticaria and 1.5 million cases of Chronic Inducible Urticaria.
• In 2024, the United States had roughly 600,000 diagnosed prevalent cases of Chronic Spontaneous Urticaria, with numbers expected to rise by 2034.
• In 2024, within the EU4 and the UK, Germany recorded the highest number of diagnosed prevalent Chronic Spontaneous Urticaria cases at around 375,000, whereas Spain reported the lowest.
• Key Chronic Spontaneous Urticaria Companies: Allakos, AstraZeneca, Biosana, Celldex Therapeutics, Celltrion, Eli Lilly and Company, Genentech, GI Innovation/Yuhan, Regeneron, GlaxoSmithKline, Taiho Pharma, Glenmark Pharmaceuticals, Gossamer Bio, Kiniksa Pharmaceuticals, Mycenax Biotech, Novartis, Regeneron, Synermore Biologics, UCB Biopharma, United BioPharma, and others
• Key Chronic Spontaneous Urticaria Therapies: Ligelizumab, Remibrutinib (LOU064), Tezepelumab, CDX-0159, GI-301, Dupilumab (DUPIXENT), UB-221, MTPS9579A, Lirentelimab (AK002), TAS5315, rilzabrutinib, GDC-0853, AZD1981, Desloratadine, and others
• The Chronic Spontaneous Urticaria epidemiology based on gender analyzed that Chronic Spontaneous Urticaria is more prominent in females in comparison to males
• The Chronic Spontaneous Urticaria market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Chronic Spontaneous Urticaria pipeline products will significantly revolutionize the Chronic Spontaneous Urticaria market dynamics.

Chronic Spontaneous Urticaria Overview
Chronic spontaneous urticaria (CSU), also known as chronic idiopathic urticaria, is a skin condition characterized by the recurrent appearance of hives (wheals or welts) and/or angioedema (swelling in deeper layers of the skin) for a duration of at least six weeks. It is termed "spontaneous" because the hives and swelling occur without an identifiable trigger or external stimulus. CSU can be associated with significant discomfort, itching, and distress, impacting the quality of life of affected individuals.

Get a Free sample for the Chronic Spontaneous Urticaria Market Report:
https://www.delveinsight.com/report-store/chronic-spontaneous-urticaria-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Key Trends in Chronic Spontaneous Urticaria Therapeutics Market:
• Shift Toward Biologics and Targeted Therapies: The market is increasingly driven by monoclonal antibodies and targeted treatments, especially for patients refractory to antihistamines, improving long-term disease control.
• Expansion Beyond Anti-IgE Therapies: While anti-IgE agents dominate, newer mechanisms such as anti-IL-5, anti-IL-4/13, and novel mast cell-targeting therapies are gaining traction in late-stage pipelines.
• Rising Focus on Personalized Treatment Approaches: Biomarker-driven patient stratification and tailored dosing strategies are emerging to optimize efficacy and reduce relapse rates in chronic spontaneous urticaria (CSU).
• Growing Pipeline and Late-Stage Clinical Activity: Increased R&D investments and a robust late-stage pipeline are accelerating innovation, with several first-in-class and best-in-class candidates advancing toward regulatory review.
• Improved Awareness and Earlier Diagnosis: Enhanced disease awareness among physicians and patients is leading to earlier diagnosis and treatment initiation, supporting sustained market growth.

Chronic Spontaneous Urticaria Epidemiology
The Chronic Spontaneous Urticaria epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Chronic Spontaneous Urticaria Epidemiology Segmentation:
The Chronic Spontaneous Urticaria market report proffers epidemiological analysis for the study period 2020-2034 in the 7MM segmented into:
• Total Prevalence of Chronic Spontaneous Urticaria
• Prevalent Cases of Chronic Spontaneous Urticaria by severity
• Gender-specific Prevalence of Chronic Spontaneous Urticaria
• Diagnosed Cases of Episodic and Chronic Chronic Spontaneous Urticaria

Download the report to understand which factors are driving Chronic Spontaneous Urticaria epidemiology trends @ Chronic Spontaneous Urticaria Epidemiology Forecast
https://www.delveinsight.com/sample-request/chronic-spontaneous-urticaria-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Recent Development In The Chronic Spontaneous Urticaria Treatment Landscape:
• In July 2025, Jasper Therapeutics, Inc. (Nasdaq: JSPR), a clinical-stage biotech developing briquilimab, a novel KIT (CD117)-targeting antibody therapy for mast cell-driven diseases such as chronic spontaneous urticaria (CSU) and chronic inducible urticaria (CIndU), has shared updated data from its BEACON Phase 1b/2a study of subcutaneous briquilimab in adults with CSU, along with a program update. Treatment with briquilimab in the 240mg and 360mg single-dose cohorts achieved rapid and deep disease control, with 8 of 9 participants (89%) attaining a complete response and 7 of 9 (78%) showing clinical response by week 2. Participants rolling over into the open-label extension at 180mg Q8W demonstrated strong efficacy, with 8 of 11 (73%) achieving a complete response by 12 weeks.
• In March 2025, Results from the Phase III REMIX-1 (NCT05030311) and REMIX-2 (NCT05032157) trials demonstrate that remibrutinib effectively alleviates symptoms of chronic spontaneous urticaria (CSU) in patients who do not respond to second-generation H1-antihistamines. The studies, published in The New England Journal of Medicine, showed that the drug has a rapid onset of action, with efficacy maintained for 24 weeks, and a favorable safety profile.
• In January 2025, Jasper Therapeutics, Inc. (Nasdaq: JSPR), a clinical-stage biotechnology company developing briquilimab, a novel c-Kit (CD117) targeting antibody for mast cell-driven diseases like chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU), and asthma, has announced positive preliminary data from its ongoing BEACON Phase 1b/2a study of subcutaneous briquilimab in adults with CSU. The study reported significant reductions in UAS7 scores, with an average change of -26.6 at eight weeks in the 240mg single-dose cohort. Multiple dosing regimens at or above 120mg showed reductions of over -25 points. Clinical responses were observed within a week, and patients across all dose levels (80mg, 120mg, 180mg, and 240mg) achieved Complete Responses (UAS7 = 0), with all participants in the 240mg single-dose group maintaining their response through eight weeks. The treatment demonstrated dose-dependent durability, reductions in serum tryptase, and a favorable safety profile.
• In November 2024, The FDA accepted the resubmission of the supplemental biologics license application for Dupixent, developed by Regeneron, for the treatment of chronic spontaneous urticaria in both adults and children.
• In November 2024, The U.S. Food and Drug Administration (FDA) has accepted the resubmission of the supplemental biologics license application (sBLA) for Dupixent (dupilumab) to treat chronic spontaneous urticaria (CSU) in adults and pediatric patients aged 12 years and older, whose condition is not sufficiently managed with H1 antihistamine treatment
• In September 2024, Evommune announced the enrollment of the first patient in a Phase II trial of EVO756 in adults with CIndU.

Chronic Spontaneous Urticaria Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Chronic Spontaneous Urticaria market or expected to get launched during the study period. The analysis covers Chronic Spontaneous Urticaria market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Chronic Spontaneous Urticaria Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Chronic Spontaneous Urticaria Therapies and Key Companies
• Ligelizumab: Novartis
• Remibrutinib (LOU064): Novartis
• Tezepelumab: Amgen
• CDX-0159: Celldex Therapeutics
• GI-301: GI Innovation
• Dupilumab (DUPIXENT): Sanofi/ Regeneron
• UB-221: United BioPharma
• MTPS9579A: Genentech
• Lirentelimab (AK002): Allakos Inc.
• TAS5315: Taiho Pharma
• rilzabrutinib: Sanofi
• GDC-0853: Genentech, Inc.
• AZD1981: AstraZeneca
• Desloratadine: Organon and Co

Discover more about therapies set to grab major Chronic Spontaneous Urticaria market share @ Chronic Spontaneous Urticaria Treatment Market
https://www.delveinsight.com/sample-request/chronic-spontaneous-urticaria-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Chronic Spontaneous Urticaria Market Drivers
• Rising prevalence and increasing diagnosis rates: Growing awareness among patients and healthcare providers is expanding the diagnosed patient pool.
• Advancements in targeted therapies: Biologics such as omalizumab and emerging anti-IgE or anti-siglec-8 therapies are improving efficacy and quality of life for patients with refractory CSU.
• Focus on patient-centric treatment approaches: Emphasis on symptom relief, reduced flare-ups, and improved quality of life is driving adoption of advanced therapies.
• Strong clinical pipeline and innovation: Ongoing development of novel small molecules and biologics is broadening treatment options.
• Regulatory support and reimbursement for rare/complex cases: Orphan drug incentives and coverage for specialty therapies encourage market growth.

Chronic Spontaneous Urticaria Market Barriers
• Limited treatment options for refractory cases: A subset of patients remains unresponsive to current therapies, posing a challenge to clinical management.
• High cost of biologic treatments: Premium pricing and reimbursement restrictions may limit access in certain regions.
• Variability in disease severity and response: Heterogeneous patient presentations make treatment optimization challenging.
• Safety and long-term tolerability concerns: Potential side effects of biologics and immunomodulators may restrict widespread use.
• Slow patient recruitment for clinical trials: Rare and complex nature of refractory CSU can hinder enrollment, delaying therapy development.

Scope of the Chronic Spontaneous Urticaria Market Report
• Study Period: 2020-2034
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Chronic Spontaneous Urticaria Companies: Allakos, AstraZeneca, Biosana, Celldex Therapeutics, Celltrion, Eli Lilly and Company, Genentech, GI Innovation/Yuhan, Regeneron, GlaxoSmithKline, Taiho Pharma, Glenmark Pharmaceuticals, Gossamer Bio, Kiniksa Pharmaceuticals, Mycenax Biotech, Novartis, Regeneron, Synermore Biologics, UCB Biopharma, United BioPharma, and others
• Key Chronic Spontaneous Urticaria Therapies: Ligelizumab, Remibrutinib (LOU064), Tezepelumab, CDX-0159, GI-301, Dupilumab (DUPIXENT), UB-221, MTPS9579A, Lirentelimab (AK002), TAS5315, rilzabrutinib, GDC-0853, AZD1981, Desloratadine, and others
• Chronic Spontaneous Urticaria Therapeutic Assessment: Chronic Spontaneous Urticaria current marketed and Chronic Spontaneous Urticaria emerging therapies
• Chronic Spontaneous Urticaria Market Dynamics: Chronic Spontaneous Urticaria market drivers and Chronic Spontaneous Urticaria market barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• Chronic Spontaneous Urticaria Unmet Needs, KOL's views, Analyst's views, Chronic Spontaneous Urticaria Market Access and Reimbursement

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: info@delveinsight.com
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting

About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

This release was published on openPR.